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For rare serious and life-threatening disorders, there is a tremendous challenge of transforming scientific discoveries
into new drug treatments. This challenge has been recognized by all stakeholders who endorse the need for flexibility
in the regulatory review process for novel therapeutics to treat rare diseases. In the United States, the best expression
of this flexibility was the creation of the Accelerated Approval (AA) pathway. The AA pathway is critically important for
the development of treatments for diseases with high unmet medical need and has been used extensively for drugs
used to treat cancer and infectious diseases like HIV.
In 2012, the AA provisions were amended to enhance the application of the AA pathway to expedite the development
of drugs for rare disorders under the Food and Drug Administration Safety and Innovation Act (FDASIA). FDASIA,
among many provisions, requires the development of a more relevant FDA guidance on the types of evidence that
may be acceptable in support of using a novel surrogate endpoint. The application of AA to rare diseases requires
more predictability to drive greater access to appropriate use of AA for more rare disease treatments that might not
be developed otherwise.
This white paper proposes a scientific framework for assessing biomarker endpoints to enhance the development
of novel therapeutics for rare and devastating diseases currently without adequate treatment and is based on the
opinions of experts in drug development and rare disease patient groups. Specific recommendations include:
1) Establishing regulatory rationale for increased AA access in rare disease programs; 2) Implementing a
Biomarker Qualification Request Process to provide the opportunity for an early determination of biomarker
acceptance; and 3) A proposed scientific framework for qualifying biomarkers as primary endpoints. The paper’s
final section highlights case studies of successful examples that have incorporated biomarker endpoints into
FDA approvals for rare disease therapies. The focus of this paper is on the situation in the Unites States, but the
recommendations are reasonably applicable to any jurisdiction.Introduction
According to the National Institutes of Health, there are
thousands of rare diseases which together affect as many
as 30 million Americans [1]. These are often serious or
life-threatening diseases and yet only there are only
about 400 drugs currently approved for rare diseases [2].* Correspondence: ekakkis@everylifefoundation.org
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heterogeneous patient populations, long time-frames for
disease progression, a poor understanding of disease
natural history, and a lack of prior clinical studies.
Recent advances in medical science have enhanced the
understanding of these disorders at the biochemical and
pathophysiologic levels and created more opportunities
to address unmet needs by developing specific thera-
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eases is now an important part of assuring that many of
the rarest and most difficult-to-treat rare diseases have
specific drugs developed.
In the United States and European Union, the regula-
tory approval of any new drug is based on its benefit-
risk ratio, which is assessed in part through the conduct
of adequate and well-controlled clinical trials in the
relevant patient population. “Benefit” refers to a demon-
strated improvement in clinical function as measured
using a clinical endpoint, which is defined broadly as the
way a patient feels, functions, or survives; “risk” refers to
the safety profile of the drug. The requirement for clin-
ical endpoints defined by the “feels, functions or sur-
vives” paradigm can be challenging as some promising
investigational treatments for serious or life-threatening
diseases may not be practically assessed for a demon-
strated improvement on clinical endpoints for many rea-
sons. For example, challenges using clinical endpoints
can occur in studies of extremely small or heterogeneous
patient populations or in diseases characterized by long
periods with subclinical or slow progression and/or that
have substantial irreversible damage at the time of
diagnosis.
To assist in the difficult challenge of transforming sci-
entific discoveries into new drug treatments for patients
with serious or life-threatening disorders, the U.S. Food
and Drug Administration (FDA), Congress, and the
public have all endorsed the need for flexibility in the
regulatory review process for rare disease drugs. This
regulatory flexibility has been designed to speed access
to new drugs, while preserving the FDA’s standards for
safety and efficacy. The best expression of this flexibility
was the creation of the Accelerated Approval (AA) path-
way in regulations promulgated by the FDA in 1992 [4].
Initially, these regulations created by the FDA were a re-
sponse to the AIDS crisis, and the growing public pres-
sure to accelerate access to medications. Congress
codified the AA pathway in 1997, with the passage of
the FDA Modernization Act (FDAMA).
The AA regulations specify when evaluating drugs for
serious and life-threatening diseases with substantial un-
met medical need, the FDA may approve a treatment
based on an efficacy evaluation using a surrogate end-
point or a clinical endpoint earlier than survival or
irreversible morbidity that is “reasonably likely to predict
clinical benefit”. Drugs granted AA are approved
with the stipulation that confirmatory studies to verify
the clinical benefit may be required as a condition of
continuing marketing authorization [4]. The regulatory
flexibility offered under the AA pathway incorporates
the public’s belief that when a patient has a lethal or
devastating disease, the benefit-risk assessment must ac-
count for the severity of the disorder and the degree ofunmet medical need, i.e., the availability (or not) of ef-
fective alternative treatment options. It is important to
emphasize, however, that AA is valuable specifically for
those situations in which timely standard approval via a
clinical endpoint is unlikely or impossible due to prac-
tical, scientific, or ethical reasons.
The use of biomarkers in the AA pathway is not
intended to substitute for clinical endpoint-based studies
in diseases with sufficient patients and readily measured
clinical endpoints that may change in reasonable time-
frames. Studies based on clinical endpoints are prefera-
ble in the development process when feasible. In rare
diseases, often the population size and heterogeneity, the
nature of the disease and the limited historical clinical
data can make traditional studies with clinical endpoints
difficult or impossible to conduct.
The AA regulations have been used successfully for
diseases such as AIDS and cancer, however, there has
been much more limited success in applying this path-
way to treatments for non-oncology, non-HIV rare dis-
eases (see Additional file 1: Table S1) [5,6]. Despite
substantial scientific insights into the pathogenesis and
pathophysiology of many rare disorders, the translation
of scientific discoveries into effective medicines for these
disorders has been notably more challenging under the
current regulatory framework, even when the under-
standing of the science underlying these diseases is far
superior to that for many multi-genic common diseases.
Rare disease treatments are sometimes approved via
the standard pathway using unvalidated biomarker end-
points due in part to flexibility in the drug review
process [7]. When flexibility has been applied regarding
a biomarker endpoint, it is often based on regulatory
precedent for the endpoint or the existence of substan-
tial clinical data with a prior treatment. For example, the
regulatory precedent for the use of ammonia levels in
urea cycle drug development is based on prior approvals
for phenylbutyrate and other urea cycle drugs, and this
precedent allowed ammonia levels to be used as the bio-
marker endpoint in the recent approval of glycerol phe-
nylbutyrate. Phenylketonuria (PKU) is a recent example
in which substantial prior clinical outcome data with a
prior treatment was important for the use of the AA
pathway to approve a novel drug, sapropterin. Saprop-
terin was approved based on the use of blood phenyl-
alanine levels as the biomarker endpoint in treating
PKU. Blood phenylalanine levels were considered pre-
dictive of the clinical outcome based on published stud-
ies of intellectual outcomes in PKU during dietary
therapy, and that these levels had been used in the clin-
ical management of PKU as well. This case illustrates
how substantial clinical data and prior treatment studies,
including dietary therapy as a treatment, as well as the
established measurement of blood levels of phenylalanine
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the approval of sapropterin. However, if there is no regula-
tory precedent for use of the relevant specific biomarker,
and if there is no substantial prior clinical data to support
the predictive value of the biomarker as a surrogate, then
qualification of a new biomarker for use as a primary end-
point in a pivotal study can be difficult or impossible [8].
There have also been a number of well known cases of
failures to properly predict clinical benefit or to fail to cap-
ture other clinical harm that provides no net clinical bene-
fit or in some cases worse mortality [8]. Although those
most infamous cases of problems in surrogate endpoints
have been in large population diseases, the use of surro-
gate or biomarker endpoints in rare diseases also needs to
be well considered to provide the most reasonable support
for the use of a biomarker as a primary endpoint in studies
that also adequately cover safety evaluation. Learning from
these failures is an important part of developing a
scientific framework for evaluating biomarkers as pri-
mary endpoints, but in any case, if good clinical end-
points exist and can be evaluated within a reasonable
practical clinical program, clinical endpoints are pref-
erable. When impractical or impossible, then the AA
pathway needs to be considered.
The AA pathway is less commonly used to approve
non-oncology, non-HIV rare disease treatments, despite
the fact that many other rare diseases pose similar levels
of severity, lethality, and unmet medical need as diseases
treated by drugs that often access the AA pathway (see
Additional file 2: Figure S1). This is largely because the
current benefit-risk assessment framework as applied to
other rare diseases has not adequately addressed uncer-
tainty about the level of evidence necessary to rely on a
novel biomarker endpoint [4,9]. The expectation for
some predictive clinical outcome data for a biomarker
endpoint has made the use of the pathway challenging,
if not impossible, for untreated rare diseases despite the
often excellent science that exists regarding the under-
lying disease, drug and/or biomarker. A re-evaluation of
the type and quality of data required for biomarker
qualification is needed to create a more relevant AA
pathway for rare diseases when the other science is
strongly supportive of the biomarker but when clinical
outcome data is limited or non-existent.
The 2012 passage of the Food and Drug Administra-
tion Safety and Innovation Act (FDASIA) [10] amended
the AA provisions to reflect recent advances in science
and to enhance the application of the AA pathway to
drugs for rare disorders, with the intent of expediting
the development and approval of new treatments. FDA-
SIA extends FDA’s authority to take into account other
available endpoints to qualify for AA and requires the
development of more relevant guidance on the types of
evidence that may be acceptable in support of using anovel surrogate endpoint. In addition, the law also con-
tains provisions to incorporate the patients’ benefit-risk
preferences into a structured evaluation process. To-
gether, these provisions create a significant and valuable
opportunity to advance the translation of promising scien-
tific discoveries into new treatments for rare disorders.
This paper provides recommendations for an effective
and detailed scientific framework to improve the rele-
vance of the AA pathway for rare diseases with unmet
medical need where sufficiently strong science exists. It
outlines the types and levels of information that increase
the predictive value of biomarker endpoints, as well as
the scientific bases sufficient to merit utilization of AA
for rare diseases using novel biomarker endpoints. The
scientific framework cannot substitute for good judg-
ment or accommodate all the complexities of the science
behind so many rare diseases, but the framework does
provide a more predictable structure for development
and review of potential biomarker endpoints. The three
main sections of the paper include an in-depth explan-
ation of pertinent recommendations to facilitate the
future development of innovative treatments for rare
diseases using the accelerated approval pathway. They
include:
 Establishing Regulatory Rationale for AA Access in
Rare Disease Programs – It is vital to establish the
key considerations specific to rare diseases that
indicate a need for regulatory flexibility, and as a
result impact the use and adequate qualification of
biomarker endpoints.
 Implementing a Biomarker Qualification Request
Process – In order to create lasting and effective
improvements in the ability to develop novel
biomarkers as surrogate primary endpoints for rare
diseases, a new regulatory process should be
implemented early in the development process,
called the Biomarker Qualification Request.
 A Proposed Scientific Framework for Qualifying
Biomarkers as Surrogate Primary Endpoints – It is
critical to develop a reasonable scientific framework
for considerations regarding the disease, drug,
biomarker and other data that can support adequate
qualification of a biomarker as a surrogate primary
endpoint that is “reasonably likely to predict clinical
benefit”.
Ultimately, the adoption and incorporation of these
recommendations for a scientific qualification frame-
work into the regulatory process will create an oppor-
tunity to increase the number of available treatments for
rare diseases when there is adequate science to support
development while maintaining the FDA’s safety and ef-
fectiveness standards.
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ples of accepted biomarker endpoints used in the drug
development process for various rare diseases. These
cases are illustrations of a handful of the rare diseases
where there has been significant progress in developing
new, sometimes life-changing, treatments. Some of these
innovations were approved using the AA pathway, while
others were not. It is important to understand these suc-
cesses in the context of the recommendations included
in the earlier sections to have a better global perspective
on these issues.
Background
Section 901 of FDASIA, entitled “Enhancement of
Accelerated Patient Access to New Medical Treat-
ments”, amended the AA provisions found in Section
506 of the U.S. Public Health Service Act [10]. These
changes are intended to take advantage of the signifi-
cant advances in science over the last several decades
to increase the application of AA to drugs for serious,
life-threatening, and rare disorders. New assay techniques
and methodologies, including advances in genomics, mo-
lecular biology, and bioinformatics, have allowed for better
understanding of disease pathophysiology and the ensuing
development of new therapies. Per FDASIA, Title IX,
Section 901 (1) C:
“As a result of these remarkable scientific and
medical advances, the FDA should be encouraged to
implement more broadly effective processes for the
expedited development and review of innovative new
medicines intended to address unmet medical needs
for serious or life-threatening diseases or conditions
including those for rare diseases or conditions,
using a broad range of surrogate or clinical end-
points and modern scientific tools earlier in the
drug development cycle when appropriate. This may
result in fewer, smaller or shorter clinical trials for the
intended patient population or targeted subpopulation
without compromising or altering the high standards of
the FDA for approval of drugs”.
FDASIA also underscores the importance of taking the
context of the specific disease state targeted by the drug
into account when conducting benefit-risk determina-
tions. It also specifically addressed AA, adding that the
FDA should consider the “severity, rarity, or prevalence
of the condition and the availability or lack of alternative
treatments” when reviewing a product which demon-
strates an effect on a surrogate endpoint.
The legislation also expands the list of potential infor-
mation to consider when assessing the predictive value
of a biomarker endpoint. Specifically, it states the evi-
dence “may include epidemiological, pathophysiological,therapeutic, pharmacologic, or other evidence developed
using biomarkers, for example, or other scientific
methods or tools”. These changes are significant, as
they increase breadth of data that may be used to provide
reasonable inferences into the predictability of benefit.
FDASIA requires the development of a guidance to
clarify the considerations unique to the application of
the AA pathway to review drugs for rare disorders [11].
Such guidance will address issues that may arise under
the AA and Fast Track processes outlined in Section 506
of the Federal Food Drug and Cosmetic Act for drugs
designated for a rare disease or condition under section
526 of the Act (21 U.S.C. 360bb). This supports the earl-
ier inclusion of rarity as a factor for AA and provides
support for the principle that rarity alone leads to signifi-
cant development issues that this guidance should address
and help to resolve: “In developing such guidance, the Sec-
retary … shall also consider any unique issues associated
with very rare diseases [emphasis added]”.
FDASIA further directs the FDA to consider how the
rarity of a disease alters the type of data that might be
available to ascertain the suitability of a surrogate end-
point, indicating that, in some cases, limited data regard-
ing the pathophysiology of disease or the pharmacology
of the drug might be sufficient:
“The Secretary shall consider how to incorporate
novel approaches to the review of surrogate endpoints
based on pathophysiologic and pharmacologic
evidence in such guidance, especially in instances
where the low prevalence of a disease renders the
existence or collection of other types of data unlikely
or impractical”. [10]
FDASIA emphasizes that the AA pathway should be
accessible to severe and very rare diseases. Additionally,
it calls for a broader-based approach to the application
of scientific data when assessing the viability of a bio-
marker as a primary endpoint for AA. For example, in
situations where long-term clinical outcome data do not
exist due to the severity and/or rarity of the disease (e.g.,
lack of qualified trial participants, time constraints, etc.),
other scientific criteria may be used if they are believed
to sufficiently meet the “reasonably likely” standard.
To ensure the changes outlined in FDASIA are imple-
mented effectively, a working group was formed (the
authors) to develop recommendations to better address
the qualification of biomarker endpoints as “reasonably
likely to predict clinical benefit” for rare disease using
a scientific framework. The scientific framework is
intended to include a broader array of considerations
regarding the disease, drug, biomarker and experimen-
tal data that help improve the biologic understanding
of the biomarker in the context of the disease and
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that the more known about the scientific basis of a
disease, the drug, and the biomarker endpoint, the
better the ability to assess predictive power of the
biomarker.
The AA pathway is critically important for the devel-
opment of treatments for rare disorders that are more
challenging to study using routine clinical study than
many fast-track-eligible common disorders [6]. However,
the Food and Drug Modernization Act (FDAMA) did
not specifically delineate considerations unique to the
review of treatments for rare diseases under AA. Add-
itional considerations are now included in FDASIA
specific to rare and very rare disorders when consider-
ing regulatory flexibility under the AA pathway. Not
all of these rare disease considerations need to be met
in order to qualify for review under the AA pathway;
rather, they should be seen as a list of specific factors
that warrant consideration when assessing the need
for regulatory flexibility in accessing the AA pathway
and for the qualification of a biomarker as a primary
endpoint in a pivotal clinical study.
Establishing regulatory rationale for AA access in rare
disease programs
FDASIA calls for the consideration of additional fac-
tors specific to rare and very serious disorders regard-
ing the potential application of regulatory flexibility
for access to the AA pathway. These factors collect-
ively provide the rationale for greater access to the AA
pathway in the development of novel therapeutics for
rare and serious diseases that currently have less than
adequate treatment options. The more factors applic-
able to any given rare and serious disease, the greater
the support for needing enhanced flexibility for qualifying
the biomarker endpoint and justifying the utilization of
the AA pathway.
 Extremely high unmet medical need
Diseases with devastating and severe outcomes and no
approved treatments deserve particular consideration
with regard to utility of AA. The unmet medical need in
these diseases greatly impacts the benefit-risk calcula-
tions made by physicians, patients, and caregivers, and
these preferences should be weighed as part of the regu-
latory review process.
 Extreme rarity of the disease
Rare disorders affecting very small populations or gen-
etic subpopulations present especially difficult challenges
that have a negative synergistic effect on drug develop-
ment, such as:1) The lack of available patients to be enrolled in
clinical trials which incorporate clinical endpoints,
negatively impacting a study’s ability to reach a
reasonable level of power to detect a statistically
significant change.
2) The need to include a significant fraction of the
total available population of patients in clinical
studies, leading to the need to accept
heterogeneous populations in terms of age,
severity and presence of specific clinical disease
symptoms, as well as stage of disease
progression.
3) The limited market potential for the drug, resulting in
small or non-existent financial incentives to invest in
the development of treatments for extremely rare
disorders, particularly without some degree of
confidence that AA is available early in the program’s
life before significant work has begun. Lack of any prior clinical studies or formally
collected clinical data
Very rare diseases with no existing treatments have
often never been studied in clinical trials. As a result,
surrounding medical literature may be limited to case
reports and small sets of patients. Frequently, rare dis-
ease patients are evaluated only in terms of disease man-
agement, and not for clinical endpoint assessments. The
lack of regulatory precedents for endpoints relevant to a
rare disease often makes the evaluation of a disease or
treatment effect so difficult or intractable that drug de-
velopment might not proceed without access to the AA
pathway.
 Slowly progressive diseases and low event rates
Many rare diseases have long and/or unpredictable
timeframes for progression, making it difficult or
impossible to conduct clinical studies within a reason-
able timeframe (i.e., ~1 year), which creates a compel-
ling need for the use of alternative biomarker
endpoints. In some cases, this may be because the
event rate is low, even if these events are very severe.
Additionally, if the clinical manifestations of the dis-
ease are irreversible and the goal of the therapy is
stabilization, achieving sufficient power to detect the
difference between placebo and treated patients is far
more difficult. In this situation, biomarkers that are
directly in the line of the pathophysiologic process
could provide a valuable assessment of treatment ef-
fect that can reasonably predict clinical benefit.
 Diseases with delays between irreversible
pathological damage and clinical diagnosis
Kakkis et al. Orphanet Journal of Rare Diseases  (2015) 10:16 Page 6 of 17Untreated rare diseases often have challenging biology in
which the disease process initiates and progresses without
clear clinical expression or diagnosis. By the time disease
progression has allowed the patient to be clinically diag-
nosed, severe late-stage and irreversible damage has already
occurred. This problem is particularly common in neuro-
logical disorders, for example, in which the plasticity and
compensatory powers of the brain continuously adapt to
the declining brain condition to maintain function. As a re-
sult, the appearance of normality is maintained despite sub-
stantial disease progression until the adaptation can no
longer compensate, at which point the patient rapidly de-
clines. Studying the treatment of a disease during this type
of early prodromal period is difficult or impossible with
clinical endpoints. The slow and inconsistent clinical
change, if any, will be undetectable, and waiting until the
patient declines may make the treatment less effective. In
some cases, treatment should begin years before disease
manifestations are evident, but earlier asymptomatic diag-
nosis may not be advocated if no treatment is available.
 Lack of readily measurable, recognized clinical
endpoints due to unusual clinical disease biology
A distinct challenge for some rare diseases is the atyp-
ical nature of their clinical outcomes, even when the
underlying cause and primary pathophysiology is under-
stood. The disease may not readily fit into existing clin-
ical models and previously identified clinical endpoints
may not be applicable. For example, in autosomal reces-
sive dystrophic epidermolysis bullosa, a genetic defi-
ciency causes the epidermal and dermal layers to split
and blister. The disease process cannot be readily mea-
sured using intermediate clinical endpoints short of
major clinical events like hospitalizations for infections
which are infrequent and avoided via symptomatic
care. In many cases, the non-specific palliative treat-
ments utilized can confound the process of clinical
evaluation, as it would of course be unethical to deny
such supportive care. In rare diseases, there may be
long-term downstream clinical outcomes such as hos-
pitalizations that could be described and appreciated,
but conducting the controlled clinical study over the
timeframe required will likely be impractical or impos-
sible as their occurrence may be too variable or their
frequency insufficient.
An effective application of AA should reflect several
important criteria that impact the ability to conduct
drug development in rare diseases. These consider-
ations are intended as a guide for determining the
need for additional regulatory flexibility in the bio-
marker qualification process to enhance development
of, and access to, innovative treatments as required
within FDASIA.Implementing a biomarker qualification request process
In the evaluation process for choosing products to de-
velop, sponsors consistently review the potential clinical
development pathway and the possible regulatory strat-
egies for approval. The lack of accepted biomarker end-
points for a rare disease with difficult to measure clinical
disease manifestations is currently interpreted by spon-
sors as too difficult a pathway to warrant development
and investment. The tendency to develop additional
drugs for rare diseases for which drugs have already
been approved is in part driven by the certainty of the
development pathway and the endpoints. The FDA’s de-
termination of the acceptability of a biomarker endpoint
is occurring too late in the process, typically at the End-
of-Phase 2 meeting, and is a considerable barrier to the
development of many novel drugs for untreated rare dis-
eases. Unfortunately, without a predictable and clearly
defined development pathway, novel and potentially life-
saving drugs for rare diseases may never even enter the
development process.
If the biomarker qualification determination can be
made earlier in the development process, before consid-
erable investment in IND-enabling work, the application
of the AA pathway would greatly increase investment in
research and development and accelerate the availability
of new treatments for the most difficult untreated rare
diseases. There is currently no regulatory process for
qualifying a biomarker endpoint for a specific disease
and drug, until typically at the End-of-Phase 2 meeting,
late in the process. Establishing a Biomarker Qualifica-
tion Request for individual drugs and diseases could
allow discussions before an IND is developed and help
guide appropriate research before substantial investment
has occurred.
The proposed Biomarker Qualification Request would
be made in parallel or before a pre-IND meeting via a
process similar to that for the pre-IND meeting. A brief-
ing book would be prepared along with questions for the
FDA, and the data considered. Based on this meeting
and discussion, the FDA could agree that for this disease
and drug in the specific proposed context, that the bio-
marker could be used as a primary endpoint with a set
of reasonable assumptions, or that it might be qualified
if certain specified data were obtained or bolstered in
the package, or the FDA might decline to qualify the
biomarker under any circumstances due to a specific set
of scientific concerns for that biomarker in that spe-
cific context of use. The timing for this process need
not be restricted to the pre-IND stage, and also could
occur later in the process if this is convenient. The
key goal is to help provide the option of earlier cer-
tainty in development and the potential to raise the
sufficient funding to develop a rare disease drug when
the pathway is clear.
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is different from the newly available qualification process
for drug development tools (DDT) which has been
outlined and explained in an FDA guidance that was
published in January 2014 [12]. The DDT qualification
process is primarily focused on broadly used bio-
markers for multiple diseases as, for example, in defin-
ing biomarkers for renal injury in drug development
for many drugs. The current process operates via the
Office of Translational Sciences within the FDA and
involves multiple stakeholders, many iterations of
evaluation and multiple years. The DDT qualification
process does not accommodate individual drugs and
individual biomarkers. Given no specific avenue for a
process like the one proposed for a specific drug, it is
difficult to engage with review divisions at the pre-
IND stage on this topic. The proposed Biomarker
Qualification Request would be managed by the ap-
propriate review division, with consultation of the
Office of Translational Sciences, and could occur as
early as the pre-IND stage. Managed well, this process
could open the door to drug development in some of
the most difficult, serious diseases that are not being
studied frequently enough today.
A proposed scientific framework for qualifying
biomarkers as surrogate primary endpoints
At the Biomarker Qualification Request meeting, a
briefing book would be prepared that would collect
the relevant data to support the qualification based on
information set forth in FDASIA. The main principle
behind these considerations is that the more that is
known about the pathophysiology of the disease, the
pharmacology of the drug, the science behind the bio-
marker, and the data in both animal models and
humans with the biomarker, the better the predictive
value for reaching the “reasonably likely to predict
clinical benefit” standard required by the AA regula-
tions. Currently, the information required to support
qualification of a biomarker as a surrogate primary
endpoint for use in a pivotal clinical study has not
been well described and is developed on a case-by-case
basis [9,13]. Unfortunately, a “case-by-case” approach to
review without any specified guidance does not provide
adequate regulatory predictability and diminishes the po-
tential investment in early development work when the
probability of using AA is uncertain. In addition, the em-
phasis on the availability of prior clinical outcome data to
support the use of a biomarker as a primary endpoint ren-
ders AA essentially inaccessible for most rare diseases.
Novel biomarker endpoints should be acceptable under
the AA pathway when the novel biomarker can be shown
to be reasonably likely to predict clinical outcomes. How-
ever, achieving this standard has been difficult because ofthe limited or lack of prior clinical outcome data. Cur-
rently, the other scientific data supporting the relevance of
a biomarker as a measure of a drug’s effect of a disease has
had limited impact on the qualification of biomarkers in
the absence of prospective clinical outcome data, despite
the data’s scientific relevance to reaching the “reasonably
likely to predict” standard. To solve this problem, a
scientific framework is proposed that establishes a
broader set of scientific considerations for qualifying a bio-
marker as a primary endpoint, without requiring prior
clinical outcome data. The ability to qualify a biomarker
using pharmacologic and pathophysiologic criteria alone is
particular important when other data such as clinical
outcome data are impossible or impractical to collect, as
explicitly noted in FDASIA [14].
For this reason, FDASIA calls for the consideration of
novel approaches to qualifying biomarkers on patho-
physiologic and pharmacologic criteria when other types
of information are not available. The development of
clear qualification considerations will encourage better
early development work by assuring a more comprehen-
sive evaluation of a biomarker at the pre-IND stage. The
data will support the basic underlying science from dis-
ease to drug to biomarker in assessing the “reasonably
likely to predict clinical benefit” standard.
Listed below are proposed pathophysiologic and
pharmacologic considerations to contribute to the confi-
dence in a biomarker’s predictive value (see Table 1). It
should be noted that while these considerations are not
absolute requirements, they should be viewed as cumula-
tive data points to support the use of a biomarker for AA
in that specific context of use.
Disease considerations
To understand the scientific basis behind how a drug’s
effects on a biomarker relate to disease outcomes, a clear
understanding of the pathophysiologic pathways in-
volved in disease pathogenesis, particularly related to the
root cause of disease and their relationship to clinical
outcomes are important. The greater the clarity of the
underlying scientific basis and the pathophysiologic
processes for a disease, the greater the confidence
regarding the interpretation of a biomarker for this
disease. The utility of animal models such as gene
knockout models for diseases of monogenic origin
should be considered particularly relevant in this con-
text. Data from the clinical literature, in vitro studies,
and relevant comparable diseases should be provided
as supportive evidence of the current understanding of
pathophysiology.
 Clear disease cause – The specific and distinct root
cause of disease, such as a specific genetic defect, the
presence of a particular autoantibody, or similar
Table 1 Considerations in establishing the scientific




Criteria for establishing the scientific
framework for qualifying biomarkers
Disease
considerations
• Clear disease cause
• Disease pathophysiology known
• No alternative disease pathogenesis pathway
Drug
considerations
• Clear structure and identity
• Direct and understood mechanism of action
• Demonstrated specific pharmacological action
• Demonstrated relevant absorption, distribution,
metabolism, and excretion (ADME) in models
Biomarker
considerations
• Directly related to pathophysiologic pathway
• Changes are sensitive and specific to changes
in clinical disease pathophysiology
• Demonstrates biological stability
• Validated or qualified assay methodology
exists for biomarker measurement
• Clinical physiological measures, also called
clinical intermediate endpoints, should be
considered predictive biomarkers when
directly relevant to major clinical problem
Preclinical
considerations
• Develop models relevant to disease
pathophysiology
• Presence of a broad and dynamic
dose–response relationship
• Compartment reflects disease tissue compartment
• Changes predict clinical changes in models
Clinical data
considerations
• Predicts clinical severity or disease progression
rate
• Sufficient breadth in detecting disease and its
range in severity
• Shows predictive value for other, similar diseases
This table lists the five primary considerations in establishing the scientific
framework for qualifying biomarkers as surrogate primary endpoints with
supporting points for each.
Kakkis et al. Orphanet Journal of Rare Diseases  (2015) 10:16 Page 8 of 17specific biological change is known or understood
based on basic science, preclinical or human data.
 Disease pathophysiology known – An understanding
of how biochemical or pathological processes result
in a disease manifestation or group of manifestations
provides increased scientific confidence in the
relevance of biomarker changes and the predictive
value of the biomarker is increased. There may be
aspects or secondary pathways that have not been
fully understood but at least one of the major
pathways of interest should be known.
 No alternative disease pathogenesis pathway –
When there is no evidence of an alternative disease
pathway, the predictive value of a biomarker is
enhanced. The existence of alternative pathways
that are poorly understood can cause uncertaintyregarding how a biomarker might impact overall
outcome [15]. However, exclusion of all possible
pathophysiologic processes is impractical and
unnecessary, particularly if the root cause of
disease pathogenesis leading to important clinical
manifestations has been identified.
Drug considerations
An understanding of the basic structure, delivery and ac-
tions of a drug relevant to changes in the biomarker can
also enhance a biomarker’s predictive value. Drugs with
direct and well-understood mechanisms of action pro-
vide greater confidence in the plausibility of a relation-
ship between a biomarker effect and a clinical outcome.
In addition, information about a compound’s distribu-
tion at appropriate effective concentrations to sites of
action and the basis for this action can further support
the likelihood of a cause-effect relationship. Conversely,
when the basis for the drug’s action is unclear or its dis-
tribution to the relevant site of action cannot be estab-
lished, then the basis for the drug’s action and the
understanding of the changes in the biomarker or dis-
ease are less certain. The data on the pharmacology of a
particular drug, then, can help to provide greater cer-
tainty that its action on a specified biomarker comes
through a pathophysiologic process associated with a
major clinical outcome. The following list includes spe-
cific drug considerations that will enhance a biomarker’s
predictive value:
 Clear structure and identity – The drug’s structure
and identity should be clear, and its production at
developmental scale in the correct active form should
be reproducible, particularly in the critical aspects
relevant to its absorption, distribution, metabolism,
and action, so that each study using the agent is
relevant.
 Direct and understood mechanism of action –
An understanding of the drug’s mechanisms con-
tributes to greater certainty about the interpret-
ability of the relationship of the drug’s action to
the biomarker and relevant clinical outcomes be-
come more predictable. Such mechanisms could
include replacement for a deficiency, enhance-
ment of a deficient activity, induction of a specific
protein, or synthetic process by a mechanism
demonstrable in vitro in cell lines or in highly
relevant animal models.
 Demonstrated specific pharmacological action –
The specific pharmacologic action and activity of
the drug should be demonstrated in either in vitro
or in vivo systems to provide confidence on the
effective concentration, distribution to the site of
action, uptake, and action.
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metabolism and excretion (ADME) in models –
When the drug’s ADME are consistent with
delivering the drug to the site of action at a relevant
concentration consistent with the plausibility of
action on the target tissue or tissues, this increases
the likelihood that the effect on a biomarker and
disease state are connected to the pathophysiologic
process and the relevant clinical outcome.
Biomarker considerations
Biomarkers as surrogate primary endpoints have had
both successes and failures in their ability to accurately
predict clinical benefit [8,15]. The large variety of bio-
markers and disease contexts can make the systematic
scientific evaluation process difficult, but there are spe-
cific points of supporting information that can enhance
the likelihood of real predictive value. While statistical
correlations established through large interventional out-
comes studies have frequently been used to develop pre-
dictive relationships, correlations alone do not provide
predictive value for a biomarker that can be evaluated
based on its biology. The biological bases of biomarkers
and their relationship to the pathophysiology of disease
represent a valuable and critical insight into predictive
value.
Biomarkers can represent any point along the patho-
physiologic process, from primary disease cause to just
before clinical outcome, and different considerations
exist for different types of surrogates (see Table 2). A
map of the pathophysiologic pathway from primary
cause, primary and secondary pathophysiologic pro-
cesses, primary and secondary clinical effects, early clin-
ical outcomes and final clinical outcomes should be
prepared to help establish the basis for the relationship
of the biomarker, and to provide a structure for verifying
the degrees of evidentiary support that exist for these
steps. Understanding the precise process level for the
biomarker and the type of biomarker is important in
guiding the type of information required about a bio-
marker and its position within the pathophysiology of
the disease and reflecting the drug’s mechanism of ac-
tion (see Table 3).
 Directly related to the pathophysiologic pathway –
The biomarker should be directly in line within the
pathophysiologic map for at least one of the major
pathophysiologic pathways. This is a critically
important factor as reviewed by Fleming [16]. An effect on a biomarker close to the primary
pathophysiologic cause of the disease is more
likely to be predictive of a meaningful impact on
the disease and is less prone to unknown links orsecondary and variable pathophysiologic
processes.
 If the biomarker is part of a secondary
pathophysiologic process, the process must be
demonstrated to be important and critical to the
clinically important pathophysiology, and the
links to the primary pathophysiology should be
demonstrated in model studies.
 A combined effect on multiple secondary
pathologic biomarkers, particularly in the setting
of an effect on a primary pathophysiologic
mechanism, should provide greater confidence
in predicting a clinically meaningful effect.
 A biomarker or intermediate clinical biomarker
close to a major pathophysiologic clinical
outcome should also be considered relevant to
and predictive of a specific clinical outcome.
 A biomarker should be matched with the most
appropriate stage of disease and used in that
context. A biomarker of early disease
pathophysiology may no longer be relevant once
significant, irreversible damage to an organ has
occurred (e.g. malformation or failure), and
conversely, a biomarker of late disease
pathophysiology may not be informative early
in the disease course.
 The biomarker should not have other
unpredictable parallel pathophysiologic pathways
that could confound the interpretation of the
biomarker. This could include a pathway for
metabolizing the biomarker or creating the
marker that is a normal biologically variant
factor. Controls for this issue should be
considered in study designs.
 Changes are sensitive and specific to changes in
clinical disease pathophysiology – The changes in
the biomarker should be sensitive and specific to
changes in the patient’s condition and disease
symptoms with a sufficient dynamic range between
normal and abnormal patients. The assay should be
able to distinguish abnormal from normal with
sufficient precision and accuracy to be a reliable
tool in the clinical setting. To ensure that various
gradations of abnormality in specimens are accurately
detected, the difference between abnormal and
normal should be large relative to the standard
deviation or coefficient of variation of the assay in a
clinical study setting. When possible, these data
should come from untreated patient specimens and
the age, gender, and ethnic origin, if relevant, should
be comparable to normal controls. If collected in
preclinical models, the ability to detect an abnormal
result with sufficient dynamic range should be
convincing. The dynamic range must be adequate to
Table 2 Example of pathophysiologic maps linking disease cause to final clinical outcomes
Disease Cause (gene or protein
level)





Late Clinical (final major
outcome/events)
Mucopolysaccharidosis




Accumulation of heparan sulfate
and dermatan sulfate GAG in cells
and tissues
GAG infiltration of upper airway
tissue
Sleep apnea, ↓O2 Sleep
deprivation
Right heart failure
GAG infiltration of lungs, liver,










Unable to do ADL Carpal
tunnel syndrome
requiring surgery
Thick heart valve Echocardiogram Enlarged heart Congestive heart failure








Phenylketonuria Defect in PAH gene that
expresses PAH that
metabolizes Phe










Myelin abnormalities Altered neuro function
Myasthenia gravis Antibody to the AchR Inhibition of Ach-based signaling Muscle weakness Drooping eyelids Difficulty
keeping eyes
open for vision
Wheelchair bound Loss of
ambulation





Deficiency of dystrophin protein Rupture of myofibrils Muscle weakness Gower’s sign
Myopathy Heart abnormality Fatigue
Decreased play
Heart failure Death










Defective binding to extracellular
matrix, sarcolemmal membrane
instability










Fabry Disease Mutation α- galactosidase
gene




CNS Stroke Neurologic deficits
Kidney Proteinuria/injury Renal failure
Heart Arrhythmia Cardiac death
The table outlines 6 diseases as examples for pathophysiologic maps. The first column represents the disease, then the cause, the primary pathophysiologic outcome of the cause through other causes, clinical
physiology and clinical outcomes. The table is intended to capture the known steps in a process, from which the location and relevance of a biomarker might be established and compared against. ADL is activities

























1° Cause Presence of a gene mutation CF mutations Measure presence of gene Not a function
RNA/gene
expression
1° pathophysiologic Expression of aberrant RNA Friedrich’s ataxia Direct impact on gene
expression
Unclear about downstream effect
RNA splicing error Fragile X
Presence of new gene expression
Enzyme or
protein level
1° pathophysiologic Enzyme activity in tissue Alpha-1-
antitrypsin
Direct measure of active
compound
Difficult to verify tissue effect
Protein in circulation
Biochemical 1° pathophysiologic Blood level of an accumulating metabolite due to a 1° block Phenylalanine in
PKU
Directly toxic compound or
active compound
Not a measure of tissue effect




2° pathophysiologic Increase in secondary metabolite that is toxic or part of
pathophysiology but not from original defect
Succinyl-lactone
in tyrosinemia I
Directly measure of toxic
effector




Biopsy 2° pathophysiologic Presence of abnormal cells or marker GL3 granules in
Fabry
Direct measure of disease or
absence of protein
Variability of biopsies, representative
sampling, variable assay methods




2° pathophysiologic Evaluate a cell removed from the patient for a phenotype or
function




2° pathophysiologic Bone structure X-ray ricket score Bone structure is nature of
disease
X-ray does not show function exactly
Presence of abnormal lesions
Change in size




1° clinical effect Tests used in clinical evaluations of clinical conditions
dependent primarily on a single tissue/organ
FVC in CF Measure of a physical
function that is directly
relevant
Not strictly a clinical outcome and hard to
gauge size of effect with clinical outcome
EMG, EKG, NCV, BAER, hand held dynamometry Muscle strength
in DMD or HIBM
Clinical
function
2° clinical effect or
intermediate clinical
measure
Tests that study integrated multiple body systems/organs,
Pulmonary function tests, sleep apnea, muscle function
6 min walk test Measure of a patient’s
function
Need to interpret magnitude of change for
relevance to patient
Walking speed
The table provides examples of different types of specimens that might be obtained from a patient or featured measured in a patient and relates these examples to their pathophysiologic stage. The goal is to
highlight the type of measures and relate these measures to the cause of disease and those steps that are further downstream. Examples for the endpoint measure in patients with specific diseases are provided to
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assay methodology could not overshadow the relevant
changes in the biomarker. Changes in preclinical
models with treatment should substantiate the
characteristics of dynamic range and responsiveness
to change over time.
 Demonstrates biologic stability – If the disease
state is relatively stable and no change in physiology
is occurring, the biomarker’s relative level should
not dramatically change. Obtaining these data may
require testing a group of individuals or preclinical
models over a significant timeframe.
 Validated or qualified assay methodology exists for
biomarker measurement – The assay methodology
for measuring the biomarker should be validated or
qualified using reasonable and relevant criteria. In
order for approval to be based on a biomarker, the
assay must reliably measure the biomarker’s value in
humans. This is of particular importance for tissue
biopsy analysis, as well as for other techniques in
which complex samples are analyzed using tools that
may be prone to variation from the sampling process,
the reagents or signal detection.
 Clinical physiological measures, also called clinical
intermediate endpoints, should be considered
predictive biomarkers when directly relevant
to major clinical problem – Many clinical
physiological tests are used to assess and treat a
specific clinical condition in common and rare
diseases. These tests are routinely accepted for
use in clinical practice for the diagnosis and man-
agement of clinical conditions in other common
diseases with similar pathophysiology. For example,
measures for joint range of motion, sleep apnea,
heart enlargement by echocardiography, and similar
tests have been associated with clinical outcomes and
are actively used to initiate treatment in common dis-
eases. If the comparability between the pathophysio-
logic processes, disease characterization, or outcomes
can be demonstrated between the rare disease and
common diseases, these tests should be considered
to have predictive value. The magnitude of the dis-
ease present and changes expected should be shown
to compare well with clinically significant changes
observed in other common diseases where the clin-
ical physiologic measure is used. Although the tests
may not have been previously used as primary end-
points, if national standards for the diagnosis and
management of the disease condition exist for other
diseases, then the comparability of the disease
process need only be supported through the use of
scientific literature or testing in order to support the
use of the test as a biomarker in a rare disorder.
Examples of such tests include pulmonary functiontests, sleep apnea testing (e.g. apnea-hypopnea index),
echocardiography (assessing cardiomegaly or poor
ejection fraction), nerve conduction velocity, or simi-
lar clinical physiology tests that capture important
clinical physiology used for the diagnosis and man-
agement of conditions. Included in this category
could be physiologic measures normally accepted as
clinical endpoints but for which the magnitude of the
change might be too small to represent a clinical
benefit, thought the direction of the change is posi-
tive for the patient. For clinical intermediate end-
points which are derived from studies in larger
population diseases, the expectation is that the sec-
ondary pathophysiologic processes should be similar
or have some commonality in the rare disease al-
though it can be hard to prove this accurately. In any
case, the magnitude of change should be physiologic-
ally important as observed in more common diseases
even if identical processes are not present. For ex-
ample, pulmonary disease in the rare mucopolysac-
charidoses, is associated with both restrictive and
obstructive components due to soft tissue and bone
disease and the improvement on restrictive disease is
part related to improvements in the lung tissue, likely
are in part similar to other inflammatory/infiltrative
diseases of the lung. Both have macrophages and
lung injury leading to interstitial changes, edema and
scarring potentially. The magnitude of the effect
should be physiologically meaningful based on what
is observed in the larger population disorders within
the specific rare disease context.
Preclinical considerations
For rare diseases, model disease treatment data are often
essential to demonstrating an important effect of a treat-
ment on a disease. The proper conduct of preclinical
studies can be important to establish a platform of data
and a framework for understanding how the disease and
drug interact, as well as how the biomarker’s behavior is
predictive. Certain critical sets of data should be ob-
tained to support the biomarker for in vitro and preclin-
ical model experiments. The more appropriate and
comparable the model is to human disease, the better it
may predict human disease. In the absence of strongly
predictive clinical models, a model that demonstrates
the treatment and biomarker effects at the level of
pathophysiology and pharmacology is sufficient, as pre-
clinical models often do not express every aspect of clin-
ical disease or progression in the same manner as in
humans. Clearly, data derived only in animal models of
less certain relationship to a disease, must be supported
by other types of data in order to allow qualification. Ex-
clusive reliance on animal models is not optimal as this
can lead to a failure in the predictive value of the
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man disease state.
The best possible data setting, whether in vitro or pre-
clinical, should be sought to support the considerations
provided below. However, for some diseases there is
no opportunity to make a preclinical model and only
in vitro models may be available or valid. When measur-
ing the clinical effects in the models is impractical or ir-
relevant, the data on the preclinical models can be based
on the pharmacologic or pathophysiological changes in
the model.
Key preclinical data to support the predictive value:
 Develop models relevant to disease pathophysiology
– Models are developed that can be studied for a
comparison of the biomarker with the pathophysiology
and using microscopic, biochemical and (if present)
clinical disease assessments. Clinical disease varies in
models and may not be the same in every respect
due to the differences in species and effects of
changes, but applicability of the models can still be
demonstrated if relevant pathophysiologic changes
can be assessed.
 Presence of a broad and dynamic dose–response
relationship – This relationship should exist
demonstrating how changes in the biomarker
reflect changes in the modeled disease levels overFigure 1 Possible dose response relationships between a biomarker and
is important and can be established to some degree in preclinical studies, wi
shows how different shapes of the curve can provide very different interpreta
change in the biomarker (b1, b2). In C1, the biomarker only covers a small ran
providing the potential error of associating change in the biomarker without mu
process too late in the clinical progression leading to most of the clinical decline
dynamic range is covering a larger part of the major decline process, and would
Establishing this relationship is an important part of interpreting the change in a
value of the biomarker; having this data is therefore important in the qualificatio
Marc Walton at the Workshop Series on this white paper development in 2012 (a reasonably wide range. When possible, it is critically
important to establish the level of biomarker
improvement associated with a potentially clinically
meaningful change in clinical disease severity or
symptomology and to assess for floor or ceiling
effects on the relationship between the biomarker
and the disease (see Figure 1). The dose–response
relationship should also be established for suboptimal
therapeutic dose levels to demonstrate the
biomarker’s sensitivity in evaluating drug effects that
are low and not likely to predict benefit. The impact
of any adverse responses (e.g., an immune response
to the therapeutic agent) should be evaluated for its
impact on the biomarker and treatment effect to
show how the biomarker predicts the treatment
effect at the biochemical or pathologic level when
altered by the adverse response. For example, if
antibodies to a drug interfere with efficacy, the
biomarker should reflect this decrease. If there is no
clear relationship between the amount of model
disease reduction and clinical outcome, then a relative
comparison toward the degree of normalization of the
pathophysiology should be used as the best estimate
of a meaningful treatment effect.
 Sampling compartment reflects disease tissue
compartment – The site of sampling, whether
blood, urine, cerebrospinal fluid, an X-ray/image, orclinical status. Understanding the biomarker-disease relationship
th support from cross-sectional or natural history studies. The graph
tions of the change in clinical status (C1, C2 and C3) for a similar
ge of the clinical disease change very early in the disease process,
ch real change in clinical status. In C3, the biomarker is measuring a
occurring before the biomarker really changes. In C2, the biomarker
therefore express a better response relationship with the clinical status.
biomarker in a clinical study setting and understanding the predictive
n process. This figure and discussion was taken from a presentation by
See www.EveryLifeFoundation.org for the slide presentation).
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ment, even if sampling the disease compartment is
not possible. A comparison of the dose–response
relationship should establish the relationship be-
tween the sampled compartment levels (e.g. blood,
urine or biopsy) and the pathology in relevant tis-
sues associated with adverse clinical outcomes. For
example, a blood test should correlate with muscle
pathology for a muscle disease treatment, showing
that the serum compartment of the biomarker is
representing the tissue compartment of interest,
muscle. If a blood biomarker were being studied for a
CNS indication, studies in model systems should show
that the blood compartment sufficiently reflects the
brain disease state. For the brain, a spinal fluid bio-
marker measurement should be shown to reflect the
brain pathology for a neurological disease treat-
ment. Confirmation of the preclinical data within
a clinical cross-sectional survey would be valu-
able when possible. To be clear, the disease
process could occur in multiple tissue compart-
ments beyond the sampled compartment, but in
this case, it should be shown that the sample
source is relevant and correlated with other
disease-relevant tissues across a variety of thera-
peutic situations or that it is at least predictive
of the important tissues in the preclinical models.
In particular, less than maximally effective levels
of treatment should be used to determine
whether the biomarker reasonably reflects the
pathologic outcome for tissues relevant to disease
outcomes to establish to a reasonable degree the
dose-biomarker response across a range of treat-
ment effect sizes.
 Changes predict clinical changes in models –
Although many preclinical models do not show
comparable clinical disease to humans, demonstra-
tion of the predictive value of the biomarker on
treatment outcome in clinical measures can still
help provide support for greater predictive value.
Clinical data considerations
The collection of clinical data has been an especially
difficult barrier to access to the AA pathway for rare
diseases, due to lack of historical data, insufficient pa-
tient numbers, and time to establish firm relation-
ships between a biomarker and clinical outcomes.
Optimally, clinical data with an effective treatment
are required to develop a predictive relationship for
clinical outcomes. When clinical outcome data does
exist for the predictive value of a biomarker in a rare
disease, these data are important to the assessment in
the qualification of a biomarker endpoint for use as a
surrogate primary endpoint. In most cases, however,longitudinal treatment studies with other agents have
never been conducted, and there is limited useful
clinical outcome information available from natural
history studies. In these cases, other types of data
must be sought when practical to support the qualifi-
cation of a surrogate. In the absence of clinical out-
come data, significant information can be obtained
from cross-sectional survey studies of patients using a
biomarker and known clinical condition and assess-
ment measures. These studies can be conducted prior
to the investment in manufacturing a drug, or before clin-
ical development has begun, to assist in the determination
of the predictive value of the biomarker when reasonable
and practical. Ideally, the studies should include patients
of different ages, severity and stages of disease. This cross-
sectional survey data can often be larger in patient num-
ber and broader in scope than the type of data provided
by a natural history study, especially if the long-term
retrospective data can be also collected during the cross-
sectional evaluation.
Natural history data can be enormously helpful in
assessing a disease and planning a development program
both in supporting a biomarker and in understanding
the disease. However, such studies are costly, take a long
time to complete, and can be prone to selection bias,
making it exceedingly difficult to collect the kind and
quality of data required for assessment of biomarkers in
a time frame that allows for a real impact on rare disease
development programs. Nonetheless, both natural his-
tory and cross-sectional data can be very useful in sup-
porting the clinical relevance of a biomarker endpoint.
The clinical data to support a biomarker should focus on
the following important considerations for a biomarker:
 Predicts clinical severity or disease progression
rate – A cross-sectional clinical survey study or
retrospective medical chart survey or natural his-
tory study can yield data to support a relationship
between the magnitude and change over time of
the biomarker measures and severity/progression/
disease level by other clinical measures. The survey
can provide multiple types of data to establish a
reasonable relationship and dynamic range for the
biomarker and a clinical parameter. This can be
done early in a program before a drug exists or be-
fore an IND is submitted.
 Sufficient breadth in detecting disease and its
range in severity – The sensitivity and dynamic
range of the biomarker must be sufficiently broad
to elucidate the important part of the spectrum of
severity of the disease using the biomarker.
Patients with mild disease or severe disease
can be distinguished from each other and from
normal patients.
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diseases – Clinical data with approved drugs from
similar diseases, for which studies have been com-
pleted, show a reasonable relationship between
changes in the biomarker and changes in clinical
endpoints. This may rarely occur, but if adequate
and reasonable parallels for another rare disease
with similar mechanisms exist, these data may be
useful. This is not to suggest that the use or failure of
biomarkers in complex multi-genic common diseases
should necessarily be applicable to results in diseases
with far more specific and clear underlying pathophysi-
ology. One example of is the use of plasma ammonia
level to approve several drugs that reduce ammonia in
patients affected by defects in the urea cycle.
Successful examples using biomarker endpoints during
rare disease drug development
A number of drugs have been approved for the treat-
ment of rare diseases using biomarker-based primary
endpoints. In most cases, the standard approval pathway
was used and involved some degree of FDA flexibility.
AA was used in some cases. While these examples
provide support for the types of information that has
been successful in achieving approval, they may not ne-
cessarily reflect the full range of information needed to
successfully develop a rare disease therapeutic.
A. Ammonia in urea cycle defects: glycerol
phenylbutyrate
The urea cycle defects cause a block in the process
that disposes of ammonia as urea, and results in eleva-
tion of toxic ammonia levels. The defect is directly in
the pathophysiologic process that creates the biomarker
ammonia, and ammonia is intrinsically toxic in excess. A
series of drugs that divert ammonia via glycine or glutam-
ine depletion have been approved using ammonia levels as
the primary indicator. The most recent example is glycerol
phenylbutyrate for urea cycle disorders that was approved
with a randomized double cross-over clinical study com-
paring it with the approved original phenylbutyrate. The
control over ammonia over a 24-hour period was com-
pared with the active control treatment. Given the history
of approvals for drugs intended for urea cycle defects
using ammonia control, and the use of ammonia control
in other diseases such as liver diseases, there has been a
precedent for ammonia control as a biomarker endpoint.
B. Phenylalanine for phenylketonuria (PKU):
Sapropterin dihydrochloride
Phenylalanine is increased in large excess in patients
due to defects in the phenylalanine hydroxylase enzyme.This enzyme is primarily responsible for initiating the
oxidative degradation of phenylalanine, and without it
the phenylalanine level rises many-fold above normal.
Phenylalanine has been shown to be directly toxic to
neurons and has been shown to predict IQ outcome in
multiple clinical studies of another therapy, dietary re-
striction of phenylalanine. The use of phenylalanine
blood level was accepted as a primary endpoint in an
89-patient randomized, placebo-controlled clinical study
in the sapropterin dihydrochloride development pro-
gram for the PKU program. Although the mechanism of
action of sapropterin was different from the compared
diet therapy used to qualify the biomarker endpoint, its
mechanism was demonstrated by labeling studies to in-
volve the restoration of the normal oxidative metabolic
pathway.
C. GL3 storage granules in the vascular endothelial
cells for Fabry disease: Agalsidase beta
Fabry disease is a lysosomal storage disorder caused by
a defect in the alpha-galactosidase gene and results in
storage in many cell types. The disease has a pro-
nounced vascular phenotype with disease most com-
monly in the kidney, heart and brain. Storage within
the endothelium is directly responsible for these vas-
cular problems. In the development of an enzyme re-
placement therapy for Fabry, it was shown that the
enzyme can clear the storage and return the endothe-
lial cells to near-normal if not normal status in terms
of GL3 granules using renal biopsies and a scoring
system. This pathologic endpoint was used in the
approval of the enzyme therapy agalsidase beta in a
58-patient randomized placebo-controlled study. The
challenge was that biopsy data can be quite variable in
sampling and the scoring can be subjective, so exten-
sive work on multiple biopsies and scoring systems
and adjudication of results was needed to develop and
gain agreement on the biopsy and the analysis of the
pathology. The confirmatory study for this approval
had some complications and though the result is de-
bated, agalsidase beta did appear to reduce the major
event rate of Fabry disease as expected.
D. Hemoglobin and platelet count for Gaucher disease:
Alglucerase
Patients with Gaucher have lysosomal storage in the
macrophages which leads to a large spleen and seques-
tration of red cells and platelets. Anemia and
thrombocytopenia can be severe and be associated
with bleeding problems. Alglucerase was studied in a
12-patient single-arm, open-label study and shown to
improve hemoglobin and platelet counts, as well as
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of the changes had not been shown to be clinically
meaningful specifically in these disease patients, it was
assumed based on general medical experience that low
hemoglobin and low platelets are problematic, that
these low levels are not resolved spontaneously, and
that the magnitude and consistency of the levels’ reso-
lution should be beneficial for patients.
E. Alpha-1-antitrypsin level for Alpha-1-antitrypsin
deficiency disease
Patients with alpha-1-antitrypsin deficiency disease
have excessive protease action that results in pulmonary
disease like emphysema over many years, and can also
be associated with liver disease. Blood-derived replace-
ment therapy was successfully approved by demonstrat-
ing the reasonable restoration of blood levels of the
protease inhibitor, although no direct proof of inhibiting
proteases at the tissue level was demonstrated. An open-
label study of one form of an alpha-1-proteinase inhibitor
(Prolastin) was studied in 19 patients over 24 weeks and
shown to achieve a serum level exceeding 80 mg/dl,
and bronchoalveolar lavage demonstrated that the
level in the plasma compartment was reaching the
alveolar space.
F. Deferasirox for reduction in iron overload in
beta-thalassemia
Deferasirox was approved using a liver biopsy measure
of iron as a primary biomarker endpoint for the reduc-
tion in iron overload derived from transfusion therapy in
the red cell disease, beta-thalassemia. In this program, a
randomized, open-label study comparing standard ther-
apy with deferoxamine compared the iron content in a
liver biopsy at 12 months to baseline content. Liver iron
content is a measure of total iron load and the drug’s ac-
tion is the direct removal of iron via the urine. The bio-
marker is in the liver, which is an important target organ
and therefore an appropriate tissue compartment for
measurement. The precision of biopsy methods can be
challenging in general, and this study randomized a total
of 586 patients to achieve their demonstration of efficacy
over 4 dose levels.
Conclusions and recommendations
The effective utilization of the AA pathway for rare dis-
eases will require development and use of a scientifically
sound framework of data for qualifying biomarker end-
points allowing the practical use of biomarkers as a
measure of efficacy. A scientific framework with defined
sets of supporting data should allow the beginning of a
more structured approach to qualifying biomarkers foruse in pivotal studies of rare disease treatments and en-
sure a wider array of important considerations are included
in this process. The proposed data that help qualify a bio-
marker will cover the disease, the drug, the biomarker, pre-
clinical data, and clinical survey or natural history data. It is
extremely important to recognize that clinical outcome
data for a novel biomarker is rarely available or plausibly
obtained for many rare diseases and therefore a systematic
process that builds support for the predictive value of a sur-
rogate using data that is available will allow more invest-
ment in innovative treatments for rare diseases.
This proposed scientific framework is a first step and
will need further evolution and development going for-
ward with experience. Regardless, the judgment and
insight of experts is needed to assess the scientific sup-
port for a biomarker, to weight the importance of the
various results and make a structured decision regarding
qualification. The evaluation process should also con-
sider the benefit-risk assessment for that disease as a
critical factor to managing the qualification process.
With a better defined process, there should be more op-
portunities to advance therapies into development.
To make the qualification of a biomarker most useful
and to enable early investment in the development of
treatment, a Biomarker Qualification Request process
should be available at the pre-IND stage for a treatment
intended to treat a rare disease. For this pre-IND Bio-
marker Qualification Request, the sponsor should provide
a briefing book containing a disease survey, the analyses of
a disease/drug/biomarker set by the proposed criteria and
verified using preclinical models, as well as any clinical
survey/natural history data on the biomarker. The review
and approval of a potential biomarker endpoint at the pre-
IND stage of development before the investment in drug
manufacturing and clinical studies will help support the
early investment in the most rare and difficult diseases. If
this can be achieved, then greater investment in develop-
ing treatments in rare diseases, especially with small popu-
lations and complex disease manifestations, will occur and
new treatments will finally be developed for so many more
untreated rare diseases using the AA pathway.
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Additional file 1: Table S1. List of FDA Drug Approvals through the
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Additional file 2: Figure S1. FDA Drug Approvals using Accelerated
Approval by Indication. This bar graph illustrates the types of serious
and/or rare diseases that have had drugs approved via the Accelerated
Approval pathway. Drug approvals using the Accelerated Approval
pathway most commonly treat cancer or HIV.
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